{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:20:47Z","timestamp":1790698847542,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014605","name":"Sage Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014605","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016372","name":"Desitin Arzneimittel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016372","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012739","name":"Zogenix","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013410","name":"LivaNova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.yebeh.2018.05.039","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T10:32:09Z","timestamp":1529663529000},"page":"94-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives"],"prefix":"10.1016","volume":"91","author":[{"given":"Susanne","family":"Schubert-Bast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Martin","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp S.","family":"Reif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kieslich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6288-9915","authenticated-orcid":false,"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2018.05.039_bb0005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pediatrneurol.2014.10.028","article-title":"Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy","volume":"52","author":"Curatolo","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0015","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0020","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","article-title":"Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function","volume":"28","author":"Meikle","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0025","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.phrs.2016.03.039","article-title":"mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis","volume":"107","author":"Citraro","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0030","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1152\/physrev.00038.2014","article-title":"mTOR in brain physiology and pathologies","volume":"95","author":"Bockaert","year":"2015","journal-title":"Physiol Rev"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0035","doi-asserted-by":"crossref","first-page":"11300","DOI":"10.1523\/JNEUROSCI.2270-05.2005","article-title":"Control of dendritic arborization by the phosphoinositide-3\u2032-kinase\u2013Akt\u2013mammalian target of rapamycin pathway","volume":"25","author":"Jaworski","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0040","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1460-9568.2006.04594.x","article-title":"Impaired synaptic plasticity in a rat model of tuberous sclerosis","volume":"23","author":"Von Der Brelie","year":"2006","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0045","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1523\/JNEUROSCI.0066-09.2009","article-title":"The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy","volume":"29","author":"Zeng","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0050","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1788","article-title":"Reversal of learning deficits in a TSC2+\/\u2212 mouse model of tuberous sclerosis","volume":"14","author":"Ehninger","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0055","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1523\/JNEUROSCI.5685-08.2009","article-title":"Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice","volume":"29","author":"Zhou","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0060","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ana.20949","article-title":"Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia","volume":"60","author":"Ljungberg","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0065","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neuropharm.2012.09.019","article-title":"mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy","volume":"69","author":"Russo","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0070","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1528-1167.2012.03513.x","article-title":"Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood\u2013brain barrier leakage but not microglia activation","volume":"53","author":"van Vliet","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0075","article-title":"Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury","volume":"8","author":"Guo","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035885","article-title":"The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway","volume":"7","author":"Talos","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0085","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/01.wnl.0000250330.44291.54","article-title":"Cognitive prognosis of patients with tuberous sclerosis complex","volume":"68","author":"Winterkorn","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0090","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1212\/01.wnl.0000280579.04974.c0","article-title":"Cognitive impairment in tuberous sclerosis complex is a multifactorial condition","volume":"70","author":"Jansen","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0095","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yebeh.2017.02.007","article-title":"Influence of seizures on early development in tuberous sclerosis complex","volume":"70","author":"Capal","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0100","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/0883073807309250","article-title":"Clinical presentation and diagnosis of tuberous sclerosis complex in infancy","volume":"23","author":"Datta","year":"2008","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0105","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-018-0764-z","article-title":"Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures?","volume":"13","author":"S\u0142owi\u0144ska","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pediatrneurol.2015.09.013","article-title":"Clinical electroencephalographic biomarker for impending epilepsy in asymptomatic tuberous sclerosis complex infants","volume":"54","author":"Wu","year":"2016","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0115","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"J\u00f3\u017awiak","year":"2011","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0120","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ejpn.2012.05.004","article-title":"Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations","volume":"16","author":"Curatolo","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0125","article-title":"Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0130","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/epi.13050","article-title":"Epilepsy in children with tuberous sclerosis complex: chance of remission and response to antiepileptic drugs","volume":"56","author":"Overwater","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/11536940-000000000-00000","article-title":"Management of seizures in Lennox\u2013Gastaut syndrome","volume":"13","author":"Crumrine","year":"2011","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0140","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/j.1528-1167.2005.00266.x","article-title":"Tuberous sclerosis complex and the ketogenic diet","volume":"46","author":"Kossoff","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.14581\/jer.17008","article-title":"Ketogenic diet for the management of epilepsy associated with tuberous sclerosis complex in children","volume":"7","author":"Park","year":"2017","journal-title":"J Epilepsy Res"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0150","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1111\/j.1528-1167.2011.02981.x","article-title":"The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway","volume":"52","author":"McDaniel","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053565","article-title":"Predictors of seizure outcomes in children with tuberous sclerosis complex and intractable epilepsy undergoing resective epilepsy surgery: an individual participant data meta-analysis","volume":"8","author":"Fallah","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0160","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1542\/peds.2005-1206","article-title":"Epilepsy surgery in young children with tuberous sclerosis: results of a novel approach","volume":"117","author":"Weiner","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0165","article-title":"Changing global trends in seizure outcomes following resective surgery for tuberous sclerosis in children with medically intractable epilepsy","volume":"2012","author":"Ibrahim","year":"2012","journal-title":"Epilepsy Res Treat"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0170","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"The Lancet"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180939","article-title":"Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study","volume":"12","author":"Bissler","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0180","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0883073808324535","article-title":"Rapamycin reduces seizure frequency in tuberous sclerosis complex","volume":"24","author":"Muncy","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0185","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejpn.2013.06.002","article-title":"Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?","volume":"17","author":"Wiegand","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0190","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0195","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-016-0530-z","article-title":"Efficacy and safety of everolimus in children with TSC - associated epilepsy \u2013 pilot data from an open single-center prospective study","volume":"11","author":"Samueli","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0200","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0205","first-page":"1","article-title":"Everolimus dosing recommendations for tuberous sclerosis complex\u2013associated refractory seizure","volume":"00","author":"Franz","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0210","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejpn.2009.03.003","article-title":"Early control of seizures improves long-term outcome in children with tuberous sclerosis complex","volume":"14","author":"Bombardieri","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0215","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pediatrneurol.2017.05.014","article-title":"Early detection of tuberous sclerosis complex: an opportunity for improved neurodevelopmental outcome","volume":"76","author":"Chung","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0220","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.pediatrneurol.2015.01.004","article-title":"Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex","volume":"52","author":"Goyer","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0225","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1007\/s00246-017-1688-4","article-title":"Regression of neonatal cardiac rhabdomyoma in two months through low-dose everolimus therapy: a report of three cases","volume":"38","author":"Chang","year":"2017","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0230","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00246-016-1528-y","article-title":"Accelerated cardiac rhabdomyoma regression with everolimus in infants with tuberous sclerosis complex","volume":"38","author":"Aw","year":"2017","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0235","first-page":"397","article-title":"Regression of massive cardiac rhabdomyoma on everolimus therapy","volume":"58","author":"Hoshal","year":"2016","journal-title":"Pediatr Int Off J Jpn Pediatr Soc"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0240","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejpn.2015.12.005","article-title":"Early onset epileptic encephalopathy or genetically determined encephalopathy with early onset epilepsy? Lessons learned from TSC","volume":"20","author":"Curatolo","year":"2016","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0245","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejpn.2017.07.018","article-title":"Dramatic relapse of seizures after everolimus withdrawal","volume":"22","author":"Mingarelli","year":"2018","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0250","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1212\/WNL.0000000000003400","article-title":"Long-term treatment of epilepsy with everolimus in tuberous sclerosis","volume":"87","author":"Krueger","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0255","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejpn.2013.03.002","article-title":"Long-term effect of everolimus on epilepsy and growth in children under 3\u202fyears of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"17","author":"Kotulska","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2018.05.039_bb0260","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/epi.13782","article-title":"Prospective clinical trials to investigate clinical and molecular biomarkers","volume":"58","author":"Auvin","year":"2017","journal-title":"Epilepsia"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018302725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018302725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:25:25Z","timestamp":1761503125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505018302725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":52,"alternative-id":["S1525505018302725"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.05.039","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.05.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}